Abstract
N-methyl-D-aspartate (NMDA) receptors play essential roles in the normal physiology of neurons, and these receptors are also largely responsible for glutamate-induced excitotoxicity. Since treatments of glutamate-induced excitotoxicity by NMDA receptor inhibitors often result in adverse side effects, alternative treatment approaches have been actively sought in recent years. One potential approach is to target proteins and enzymes down stream of the NMDA receptor signaling pathways. Extensive studies in recent years have demonstrated that PDZ domains of PSD-95 play critical roles in scaffolding the NMDA receptor/neuronal nitric oxide synthase pathway. Therefore, PSD-95 PDZ domains become attractive targets for treatment of glutamate-induced overproduction of nitric oxide. The strategy is to develop small compounds that can effectively block protein-protein interactions mediated by the PDZ domains of PSD-95. Biochemical and structural studies of PDZ/target interactions have indicated that developing small molecules to compete with PDZ targets is a feasible approach. We provide an example demonstrating the discovery and further development of small molecules capable of disrupting PSD-95/NMDA receptor and/or PSD-95/neuronal nitric oxide synthase complexes.
Keywords: Excitotoxicity, stroke, NMDA receptor, PSD-95, PDZ, neuronal nitric oxide synthase, protein-protein interaction
Current Topics in Medicinal Chemistry
Title: Targeting PDZ Domain Proteins for Treating NMDA Receptor-Mediated Excitotoxicity
Volume: 6 Issue: 7
Author(s): Wenyu Wen, Wenning Wang and Mingjie Zhang
Affiliation:
Keywords: Excitotoxicity, stroke, NMDA receptor, PSD-95, PDZ, neuronal nitric oxide synthase, protein-protein interaction
Abstract: N-methyl-D-aspartate (NMDA) receptors play essential roles in the normal physiology of neurons, and these receptors are also largely responsible for glutamate-induced excitotoxicity. Since treatments of glutamate-induced excitotoxicity by NMDA receptor inhibitors often result in adverse side effects, alternative treatment approaches have been actively sought in recent years. One potential approach is to target proteins and enzymes down stream of the NMDA receptor signaling pathways. Extensive studies in recent years have demonstrated that PDZ domains of PSD-95 play critical roles in scaffolding the NMDA receptor/neuronal nitric oxide synthase pathway. Therefore, PSD-95 PDZ domains become attractive targets for treatment of glutamate-induced overproduction of nitric oxide. The strategy is to develop small compounds that can effectively block protein-protein interactions mediated by the PDZ domains of PSD-95. Biochemical and structural studies of PDZ/target interactions have indicated that developing small molecules to compete with PDZ targets is a feasible approach. We provide an example demonstrating the discovery and further development of small molecules capable of disrupting PSD-95/NMDA receptor and/or PSD-95/neuronal nitric oxide synthase complexes.
Export Options
About this article
Cite this article as:
Wen Wenyu, Wang Wenning and Zhang Mingjie, Targeting PDZ Domain Proteins for Treating NMDA Receptor-Mediated Excitotoxicity, Current Topics in Medicinal Chemistry 2006; 6 (7) . https://dx.doi.org/10.2174/156802606776894474
DOI https://dx.doi.org/10.2174/156802606776894474 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimers Disease
Current Alzheimer Research Phosphodiesterase Inhibitors for Cognitive Enhancement
Current Pharmaceutical Design Nitric Oxide Supplementation in Postischemic Acute Renal Failure: Normotension Versus Hypertension
Current Pharmaceutical Biotechnology An Optimal Combination of Chemically Pure Compounds from <i>Salvia miltiorrhiza</i> for Inhibiting Cell Proliferation
Cardiovascular & Hematological Agents in Medicinal Chemistry The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Neuroimmune Activation in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets In Silico Study of Flavonoids as DPP-4 and α-glucosidase Inhibitors
Letters in Drug Design & Discovery The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer
Current Drug Targets Recent Developments in Cardiovascular Drug Therapy: Treatment of Atrial Arrhythmias with New Class III Drugs and beyond
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Intracoronary Injection of Glycoprotein IIb/IIIa, Abciximab, as Adjuvant Therapy in Primary Coronary Intervention
Cardiovascular & Hematological Agents in Medicinal Chemistry Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Comparison of Amniotic Fluid Index and Single Deepest Vertical Pocket
Current Women`s Health Reviews EDITORIAL (Hot Topic: Renal Sympathetic Denervation and Cardiovascular Disease: Past, Present and Future)
Current Clinical Pharmacology PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?
Current Pharmaceutical Design Fondaparinux for the Prevention or Treatment of Venous ThromboEmbolism Related to Lower Limb Trauma: Evidence Today
Current Vascular Pharmacology Is There Any Scientific Basis of Hawan to be Used in the Alzheimer’s Disease Prevention/Cure?
Current Traditional Medicine Adult Stem Cells and the Clinical Arena: Are we Able to Widely Use this Therapy in Patients with Chronic Limbs Arteriopathy and Ischemic Ulcers without Possibility of Revascularization?
Cardiovascular & Hematological Agents in Medicinal Chemistry Endothelial Endocytic Pathways: Gates for Vascular Drug Delivery
Current Vascular Pharmacology Meet Our Editorial Board Member
Current Medical Imaging